This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer

< Back

Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer


Cancer and Palliative Care

December 2019

Selpercatinib is in clinical development for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and at the metastatic stage the disease has already spread from the lungs to other sites. Around 2% of these patients will have tumours that contain fusion mutations in the RET gene. Cells in these tumour produce altered RET signalling receptors that allow uncontrolled cancer growth. Currently the only treatment options that attempt to inhibit RET fusion-positive tumour activity are nonselective multikinase inhibitors.
Selpercatinib is a first-in-class oral precision cancer medicine designed to selectively bind to cancers that harbour genetic abnormalities in the RET proteins. This binding inhibits the RET receptor signalling which in turn inhibits the tumour cell growth and may also prevent resistance to the treatment from developing. Selpercatinib is being developed for NSCLC and other advanced solid tumours with RET genetic alterations with early results indicating significantly improved outcomes. If licensed, selpercatinib will offer a first-in-class treatment option for RET-fusion positive NSCLC, who currently have no highly selective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts